Market Closed -
Euronext Paris
11:35:15 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
1.936
EUR
|
+2.76%
|
|
-1.63%
|
-45.54%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
142.4
|
237
|
895.3
|
332.2
|
98.86
|
98.86
|
-
|
Enterprise Value (EV)
1 |
142.4
|
237
|
895.3
|
332.2
|
98.86
|
98.86
|
98.86
|
P/E ratio
|
-
|
-
|
-
|
-24.4
x
|
-5.09
x
|
-5.38
x
|
-5.23
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
83.7
x
|
151
x
|
566
x
|
-
|
106
x
|
99.9
x
|
89.9
x
|
EV / Revenue
|
83.7
x
|
151
x
|
566
x
|
-
|
106
x
|
99.9
x
|
89.9
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-5.18
x
|
-5.53
x
|
-5.26
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-5.26
x
|
-5.5
x
|
-5.2
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-19%
|
-18.2%
|
-19.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,064
|
44,060
|
45,540
|
46,861
|
51,067
|
51,067
|
-
|
Reference price
2 |
3.468
|
5.380
|
19.66
|
7.090
|
1.936
|
1.936
|
1.936
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
3/1/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1.701
|
1.571
|
1.583
|
-
|
0.93
|
0.99
|
1.1
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-19.1
|
-17.89
|
-18.78
|
EBIT
1 |
-
|
-17.47
|
-
|
-
|
-15.96
|
-15.91
|
-15.8
|
Operating Margin
|
-
|
-1,112.29%
|
-
|
-
|
-1,716.13%
|
-1,607.07%
|
-1,436.36%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-13.62
|
-19.64
|
-18.77
|
-18
|
Net margin
|
-
|
-
|
-
|
-
|
-2,111.83%
|
-1,895.96%
|
-1,636.36%
|
EPS
2 |
-
|
-
|
-
|
-0.2900
|
-0.3800
|
-0.3600
|
-0.3700
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-18.81
|
-17.99
|
-19
|
FCF margin
|
-
|
-
|
-
|
-
|
-2,022.58%
|
-1,817.17%
|
-1,727.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
3/1/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-18.8
|
-18
|
-19
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.48
|
-
|
-
|
-
|
0.05
|
0.06
|
0.5
|
Capex / Sales
|
28.45%
|
-
|
-
|
-
|
5.38%
|
6.06%
|
45.45%
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
3/1/23
|
-
|
-
|
-
|
Last Close Price
1.936
EUR Average target price
6.895
EUR Spread / Average Target +256.15% Consensus |
1st Jan change
|
Capi.
|
---|
| -45.54% | 106M | | +5.31% | 70.44B | | +10.97% | 8.94B | | -16.83% | 4.75B | | +43.48% | 4.5B | | +3.20% | 3.85B | | +18.82% | 2.38B | | -21.36% | 2.34B | | -29.67% | 2.2B | | +8.38% | 1.96B |
Specialty & Advanced Pharmaceuticals
|